These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38695169)

  • 1. Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia.
    Béliard S; Saheb S; Litzler-Renault S; Vimont A; Valero R; Bruckert É; Farnier M; Gallo A
    Arterioscler Thromb Vasc Biol; 2024 Jun; 44(6):1447-1454. PubMed ID: 38695169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evinacumab for Homozygous Familial Hypercholesterolemia.
    Raal FJ; Rosenson RS; Reeskamp LF; Hovingh GK; Kastelein JJP; Rubba P; Ali S; Banerjee P; Chan KC; Gipe DA; Khilla N; Pordy R; Weinreich DM; Yancopoulos GD; Zhang Y; Gaudet D;
    N Engl J Med; 2020 Aug; 383(8):711-720. PubMed ID: 32813947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
    Wiegman A; Greber-Platzer S; Ali S; Reijman MD; Brinton EA; Charng MJ; Srinivasan S; Baker-Smith C; Baum S; Brothers JA; Hartz J; Moriarty PM; Mendell J; Bihorel S; Banerjee P; George RT; Hirshberg B; Pordy R
    Circulation; 2024 Jan; 149(5):343-353. PubMed ID: 37860863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Will evinacumab become the standard treatment for homozygous familial hypercholesterolemia?
    Doggrell SA
    Expert Opin Biol Ther; 2021 Mar; 21(3):299-302. PubMed ID: 33295805
    [No Abstract]   [Full Text] [Related]  

  • 5. Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry.
    D'Erasmo L; Bini S; Casula M; Gazzotti M; Bertolini S; Calandra S; Tarugi P; Averna M; Iannuzzo G; Fortunato G; Catapano AL; Arca M;
    Eur J Prev Cardiol; 2024 Jun; 31(8):1038-1047. PubMed ID: 38374534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy.
    Gaudet D; Greber-Platzer S; Reeskamp LF; Iannuzzo G; Rosenson RS; Saheb S; Stefanutti C; Stroes E; Wiegman A; Turner T; Ali S; Banerjee P; Drewery T; McGinniss J; Waldron A; George RT; Zhao XQ; Pordy R; Zhao J; Bruckert E; Raal FJ
    Eur Heart J; 2024 Jul; 45(27):2422-2434. PubMed ID: 38856678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
    Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
    Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries.
    Reijman MD; Tromp TR; Hutten BA; Hovingh GK; Blom DJ; Catapano AL; Cuchel M; Dann EJ; Gallo A; Hudgins LC; Raal FJ; Ray KK; Sadiq F; Soran H; Groothoff JW; Wiegman A; Kusters DM; ;
    Lancet Child Adolesc Health; 2024 Jul; 8(7):491-499. PubMed ID: 38759658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.
    Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G
    Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.
    Stefanutti C; Blom DJ; Averna MR; Meagher EA; Theron Hd; Marais AD; Hegele RA; Sirtori CR; Shah PK; Gaudet D; Vigna GB; Sachais BS; Di Giacomo S; du Plessis AM; Bloedon LT; Balser J; Rader DJ; Cuchel M;
    Atherosclerosis; 2015 Jun; 240(2):408-14. PubMed ID: 25897792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.
    Bruckert E; Kalmykova O; Bittar R; Carreau V; Béliard S; Saheb S; Rosenbaum D; Bonnefont-Rousselot D; Thomas D; Emery C; Khoshnood B; Carrié A
    Atherosclerosis; 2017 Feb; 257():130-137. PubMed ID: 28131047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.
    Raal FJ; Hegele RA; Ruzza A; López JAG; Bhatia AK; Wu J; Wang H; Gaudet D; Wiegman A; Wang J; Santos RD
    Arterioscler Thromb Vasc Biol; 2024 May; 44(5):1156-1164. PubMed ID: 38545781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.
    Alonso R; Arroyo-Olivares R; Díaz-Díaz JL; Fuentes-Jiménez F; Arrieta F; de Andrés R; Gonzalez-Bustos P; Argueso R; Martin-Ordiales M; Martinez-Faedo C; Illán F; Saenz P; Donate JM; Sanchez Muñoz-Torrero JF; Martinez-Hervas S; Mata P
    Atherosclerosis; 2024 Jun; 393():117516. PubMed ID: 38523000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia.
    Pirillo A; Catapano AL
    Expert Opin Biol Ther; 2022 Jul; 22(7):813-820. PubMed ID: 35698895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evinacumab: Mechanism of action, clinical, and translational science.
    Dingman R; Bihorel S; Gusarova V; Mendell J; Pordy R
    Clin Transl Sci; 2024 Jun; 17(6):e13836. PubMed ID: 38845393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia.
    Gu J; Kuznik A; Quon P; Chauhan A; Sravya TS; Raal FJ
    Eur J Prev Cardiol; 2023 Nov; 30(17):1874-1880. PubMed ID: 37314419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marked plaque regression in homozygous familial hypercholesterolemia.
    Reeskamp LF; Nurmohamed NS; Bom MJ; Planken RN; Driessen RS; van Diemen PA; Luirink IK; Groothoff JW; Kuipers IM; Knaapen P; Stroes ESG; Wiegman A; Hovingh GK
    Atherosclerosis; 2021 Jun; 327():13-17. PubMed ID: 34004483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia.
    Raal FJ; Rosenson RS; Reeskamp LF; Kastelein JJP; Rubba P; Duell PB; Koseki M; Stroes E; Ali S; Banerjee P; Chan KC; Khilla N; McGinniss J; Pordy R; Zhang Y; Gaudet D
    JACC Adv; 2023 Nov; 2(9):100648. PubMed ID: 38938723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia.
    Stefanutti C
    Curr Atheroscler Rep; 2020 Jun; 22(8):38. PubMed ID: 32557261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey.
    D'Erasmo L; Gallo A; Cefalù AB; Di Costanzo A; Saheb S; Giammanco A; Averna M; Buonaiuto A; Iannuzzo G; Fortunato G; Puja A; Montalcini T; Pavanello C; Calabresi L; Vigna GB; Bucci M; Bonomo K; Nota F; Sampietro T; Sbrana F; Suppressa P; Sabbà C; Fimiani F; Cesaro A; Calabrò P; Palmisano S; D'Addato S; Pisciotta L; Bertolini S; Bittar R; Kalmykova O; Béliard S; Carrié A; Arca M; Bruckert E
    Orphanet J Rare Dis; 2021 Sep; 16(1):381. PubMed ID: 34496902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.